- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03548129
the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria
Empirical Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria
Study Overview
Status
Conditions
Detailed Description
This study aims to compare between the efficacy of empirical use of fosfomycin trometamol and the use of selected antimicrobials according to urinary culture and sensitivity in curing asymptomatic bacteriuria.
All women included in the study will be counseled regarding mode of intervention and informed consent will be obtained. All cases will be subjected to complete history taking, routine antenatal examination and investigations including complete blood picture, kidney functions and urine analysis, treatment of genital infection if diagnosed. Routine obstetric ultrasound examination.
Patients will be randomized into two groups:
Group (A): Fosfomycin group (FG); where all patients will receive empirical 3 gm oral fosfomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.
The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.
Nature: also known as phosphomycin, phosphonomycin, is a broad-spectrum antibiotic, produced by certain Streptomyces species, although it can now be made by chemical synthesis.
Trade name: Monuril Company: Zambon, Pharma Con Company, Switzerland
- Group (B): Culture specific group (CG): where all patients will receive oral antibiotic according to urine culture and sensitivity, oral antibiotics will be given in the form of five days regimen.
How the urine sample will be collected? The caregiver will give the patient a sterile cup and lid, and advice her to wash herself completely then clean the perineal area from anterior to posterior by water and in standing position as male begin to urinate then stop urinating put the sterile cup and catch the rest of urine in it. Do not touch the inside of the cup or the lid. Put the lid on the cup.
One week after completing the course of treatment all patients included in the study will be subjected to colony count evaluation, to figure out the need for:
- Urine culture in fosfomycin group in case of inadequate response to treatment and to give antibiotic according.
- The change of duration or the type of antibiotic in case of inadequate response to initial treatment in the culture group.
Outcomes
Primary:
- Resolution of asymptomatic bacteriuria as measured by colony count.
- Time frame: 1 week
Secondary:
- Side effects of fosfomycin as, nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group
- Need for further treatment, either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response.
- Need for further investigations, as urine culture and sensitivity for fosfomycin group in case of inadequate response on empirical treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pregnant patients from 13 weeks to 36 weeks gestation.
- Pus cells in urine analysis >5/HPF.
- ≥ 105 colony-forming units (CFU) per millilitre of the same microorganisms in two consecutive cultures.
- No symptoms or sings suggestive of urinary tract infection.
Exclusion Criteria:
- Presence of any urinary symptoms as burning micturition, hesitancy
- Fever and loin pain.
- Diabetes mellitus.
- Known to be allergic from any of the antimicrobial ingredients.
- Not using any antimicrobial during the course of treatment for any other infection.
- Not known to have any congenital urinary anomalies.
If the patient is taking medications that interact with fosfomycin as:
- Anorexiants (eg, phentermine) or certain sympathomimetics (eg, albuterol, amphetamine, pseudoephedrine) because the risk of their side effects may be increased by fosfomycin.
- Lithium or tetracyclines because their effectiveness may be decreased by fosfomycin.
- Metoclopramide because it may decrease fosfomycin's effectiveness.
- Impaired kidney functions (creatinine's clearance is <80 ml/min.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fosfomycin group (FG)
Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder. The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form. Response to treatment will be assessed by post-treatment urine culture. |
Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
|
Active Comparator: Culture specific group (CG):
Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen. Response to treatment will be assessed by post-treatment urine culture. |
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
Culture-specific antibiotic treatment for 5 days
Susceptibility of urinary pathogens to various antimicrobials
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of asymptomatic bacteriuria
Time Frame: 1 week
|
Decline in colony forming unit (CFU)/mL or absence of bacterial growth after treatment
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for further treatment
Time Frame: 1 week
|
Either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response.
|
1 week
|
Need for further investigations
Time Frame: 1 week
|
Need for urine culture and sensitivity in fosfomycin group in case of inadequate response on empirical treatment.
|
1 week
|
Incidence of adverse drug reactions .
Time Frame: 1 week
|
Incidence of adverse drug reactions as nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group
|
1 week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- phosphomycin
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection
-
Gloucestershire Hospitals NHS Foundation TrustUnknownCatheter Infection | Urinary Tract Infection in Pregnancy | Urinary Tract Infection Following Delivery
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
National Institute of Allergy and Infectious Diseases...TerminatedUrinary Tract InfectionUnited States
-
University Of PerugiaUnknownUrinary Tract Infection
-
NanovibronixShaare Zedek Medical CenterUnknownUrinary Tract InfectionIsrael
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)UnknownUrinary Tract InfectionCanada
-
Hadassah Medical OrganizationUnknown
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
Hospital de Clinicas de Porto AlegreUnknownUrinary Tract Infection | Respiratory Tract InfectionBrazil
-
Bactiguard ABRehab Station StockholmCompletedComplications; Catheter, Urinary Infection or InflammationSweden